Effects of Quinine, Quinidine, and Chloroquine on α9α10 Nicotinic Cholinergic Receptors

  title={Effects of Quinine, Quinidine, and Chloroquine on $\alpha$9$\alpha$10 Nicotinic Cholinergic Receptors},
  author={Jimena A. Ballestero and Paola V. Plazas and Sebastian Kracun and Mar{\'i}a Eugenia G{\'o}mez-Casati and Julian Taranda and Carla V. Rothlin and Eleonora Katz and Neil S Millar and Ana Bel{\'e}n Elgoyhen},
  journal={Molecular Pharmacology},
  pages={822 - 829}
In this study, we report the effects of the quinoline derivatives quinine, its optical isomer quinidine, and chloroquine on α9α10-containing nicotinic acetylcholine receptors (nAChRs). The compounds blocked acetylcholine (ACh)-evoked responses in α9α10-injected Xenopus laevis oocytes in a concentration-dependent manner, with a rank order of potency of chloroquine (IC50 = 0.39 μM) > quinine (IC50 = 0.97 μM) ∼ quinidine (IC50 = 1.37 μM). Moreover, chloroquine blocked ACh-evoked responses on rat… 

Figures and Tables from this paper

Effects of Quinine, Quinidine and Chloroquine on Human Muscle Nicotinic Acetylcholine Receptors

Quinine is effective at the muscular nAChRs close to therapeutic blood concentrations required for the therapy and prophylaxis of nocturnal leg cramps, suggesting that the clinically proven efficacy of quinine could be based on targeting nA ChRs.

The Antimalarial Drug Proguanil Is an Antagonist at 5-HT3 Receptors

It is demonstrated that proguanil competitively inhibits 5-HT3 receptors, with an IC50 that exceeds whole-blood concentrations following its oral administration, which may be responsible for the occasional gastrointestinal side effects, nausea, and vomiting reported following its use.

The 5-HT3 receptor as a therapeutic target

The structure, function and distribution of 5-HT3 receptors and how this may influence their role in disease are looked at.

Triphenylphosphine oxide is a potent and selective inhibitor of the transient receptor potential melastatin-5 ion channel.

triphenylphosphine oxide (TPPO) is the most potent TRPM5 inhibitor described to date and is the first demonstrated to exhibit selectivity over other channels.

(E)-3-Furan-2-yl-N-p-tolyl-acrylamide and its Derivative DM489 Decrease Neuropathic Pain in Mice Predominantly by α7 Nicotinic Acetylcholine Receptor Potentiation.

The electrophysiological results support the notion that α7 nAChR potentiation is likely the predominant molecular mechanism underlying the observed anti-nociceptive pain activity of these compounds.

Neuronal Nicotinic Receptors: One Hundred Years of Progress

This chapter reviews some of the fundamental aspects of nicotinic receptors, with emphasis on the differences in pharmacology among the receptor subtypes and their unusual regulation by exposure to nicotine.

The Effects of Chloroquine and Hydroxychloroquine on ACE2-Related Coronavirus Pathology and the Cardiovascular System: An Evidence-Based Review

CQ and HCQ could potentially be useful drugs in the treatment of COVID-19 and other ACE2 involved virus infections, but the antiviral effects of CQ andHCQ need to be tested in more well-designed clinical randomized studies and their actions on the CV system need to been further elucidated.



Block of the α9 nicotinic receptor by ototoxic aminoglycosides

Effects of quinine on the excitability and voltage-dependent currents of isolated spiral ganglion neurons in culture.

Quinine-induced tinnitus may be explained by its broadening of action potentials while the drug's inhibition on INa may result in hearing loss by making the conversion from excitatory postsynaptic potentials to the generation ofaction potentials more difficult.

Salicylate, mefenamate, meclofenamate, and quinine on cochlear potentials

  • Jean-Luc FuelR. BobbinM. Fallon
  • Medicine, Biology
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • 1990
The results suggest that salicylate-induced hearing loss is not caused by either antagonism of the hair cell transmitter or cyclooxygenase inhibition, nor is it caused by the same mechanism that causes quinine- induced hearing loss.

Pharmacological Properties of α9α10 Nicotinic Acetylcholine Receptors Revealed by Heterologous Expression of Subunit Chimeras

Subunit chimeras have been constructed that contain the extracellular, ligand binding domain of the α9 or α10 subunits fused to the C-terminal domain ofThe 5-hydroxytryptamine type 3A (5HT3A) subunit, providing evidence of a requirement for coassembly of α9 and α10 for the efficient formation of a nicotinic binding site.

Quinidine normalizes the open duration of slow‐channel mutants of the acetylcholine receptor

The hypothesis that quinidine can normalize the prolonged channel opening events of slow-channel mutants of human AChR is tested and a therapeutic effect for quInidine in the slow- channel congenital myasthenic syndrome is predicted.

The alpha9alpha10 nicotinic acetylcholine receptor is permeable to and is modulated by divalent cations.

Study of the permeability of the recombinant alpha 9 alpha 10 nicotinic acetylcholine receptor to Ca(2+), Ba(2+) and Mg( 2+) and its modulation by these divalent cations suggested changes in the apparent affinity of the alpha 9alpha 10 receptor for ACh.

Key roles of hydrophobic rings of TM2 in gating of the α9α10 nicotinic cholinergic receptor

A systematic mutagenesis of three hydrophobic rings within transmembrane region (TM) 2 of the α9α10 nicotinic cholinergic receptor (nAChR) to a hydrophilic (threonine) residue was performed and the properties of mutant receptors reconstituted in Xenopus laevis oocytes were compared.